Core Viewpoint - Onconetix, Inc. has announced a reverse stock split of 1-for-85 shares, approved by stockholders, to regain compliance with Nasdaq's minimum bid price requirement of $1.00 per share, effective June 13, 2025 [1][3][5] Group 1: Reverse Stock Split Details - The reverse stock split will reduce the number of outstanding shares from approximately 44.4 million to about 521,863 [5] - The split will be executed automatically, converting every 85 shares into one share without changing the par value, and no fractional shares will be issued [4] - Fractional shares will be compensated in cash based on the closing price on June 12, 2025 [4] Group 2: Company Overview - Onconetix, Inc. is a commercial-stage biotechnology company focused on men's health and oncology, owning products like Proclarix and ENTADFI [6] - Proclarix is an in vitro diagnostic test for prostate cancer, while ENTADFI is an FDA-approved treatment for benign prostatic hyperplasia [6]

Core Viewpoint - Onconetix, Inc. and Ocuvex Therapeutics, Inc. have signed a Non-Binding Letter of Intent for a potential business combination, which aims to enhance Onconetix's portfolio beyond oncology and increase shareholder value [1][2]. Company Overview Onconetix, Inc. - Onconetix is a commercial stage biotechnology company focused on men's health and oncology, with products like Proclarix®, an in vitro diagnostic test for prostate cancer, and ENTADFI, an FDA-approved treatment for benign prostatic hyperplasia [4]. Ocuvex Therapeutics, Inc. - Ocuvex is a privately held biopharmaceutical company specializing in ophthalmic therapeutic candidates, formed from the merger of Ocuvex Inc. and Visiox Pharmaceuticals, Inc. in August 2024. Its lead asset, Omlonti®, is an FDA-approved treatment for ocular hypertension and open-angle glaucoma [6]. Transaction Details - The proposed transaction will involve Onconetix acquiring all equity interests of Ocuvex in exchange for newly issued shares of Onconetix, with pre-closing Ocuvex equity holders expected to own approximately 90% of Onconetix post-transaction [2][3]. - The Letter of Intent indicates mutual interest but is subject to due diligence, financing, and regulatory approvals, with no assurance that a definitive agreement will be executed [3].